PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.23%
EBIT growth above 1.5x GNPX's 7.05%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
22.23%
Operating income growth above 1.5x GNPX's 7.05%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
18.34%
Net income growth above 1.5x GNPX's 6.78%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
32.95%
EPS growth above 1.5x GNPX's 6.07%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
32.95%
Diluted EPS growth above 1.5x GNPX's 5.69%. David Dodd would see if there's a robust moat protecting these shareholder gains.
21.91%
Slight or no buybacks while GNPX is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
21.91%
Slight or no buyback while GNPX is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
46.02%
OCF growth at 50-75% of GNPX's 66.89%. Martin Whitman would question if the firm lags in monetizing sales effectively.
46.06%
FCF growth 50-75% of GNPX's 67.73%. Martin Whitman would see if structural disadvantages exist in generating free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8783.56%
Negative 10Y OCF/share CAGR while GNPX stands at 85.97%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
85.25%
5Y OCF/share CAGR is similar to GNPX's 85.97%. Walter Schloss might see parallel cost profiles or expansions producing comparable cash flow.
76.39%
3Y OCF/share CAGR at 75-90% of GNPX's 85.97%. Bill Ackman would press for improvements in margin or overhead to catch up.
-13944.86%
Negative 10Y net income/share CAGR while GNPX is at 62.46%. Joel Greenblatt sees a major red flag in long-term profit erosion.
85.03%
5Y net income/share CAGR 1.25-1.5x GNPX's 62.46%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
64.22%
3Y net income/share CAGR similar to GNPX's 62.46%. Walter Schloss would attribute it to shared growth factors or demand patterns.
5293.49%
Positive growth while GNPX is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
188.65%
Positive 5Y equity/share CAGR while GNPX is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
367.41%
Positive short-term equity growth while GNPX is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.58%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-38.36%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
-22.17%
Our R&D shrinks while GNPX invests at 10.01%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-22.47%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.